Rayno Life Science Portfolio : Diagnostics and Tools, Quidel and Celera

Quidel Gabapentin to buy online (QDEL) was up 7.9% yesterday to $12.13 on volume of 375k shares. This stock is now under review and is a value buy in the $12 range. Quidel bought Diagnostic Hybrids for for $131M in Q1 bringing debt to $83M. Wedbush upgraded the stock on May 27.

follow link Celera(CRA) is being added as a http://stevestine.com/phrasinginfo buy at $7 on May 28,2010. Celera is an emerging player in molecular diagnostics and personalized medicine with quarterly revenues in the $31M range and a strong balance sheet with $319 M in cash. Celera has a strategic partner  in diagnostics with Abbott.

Next portfolio quarterly update on July 2.

Rayno Life Science Portfolio: Big winners-Abaxis, Hologic, Illumina, Inverness and SeraCare.

Below find the summary of our Diagnostics and Tools Portfolio as published on Raygent.com and Genetic Engineering News (www.genengnews.com) on Feb.2, 2009. We are currently reviewing(UR) four new stocks: Genomic Health, Genoptix,  MicroFluidics, and Neogen. All of these stocks are “holds”.  Immucor (BLUD) has support at 20 and is now in the portfolio.



3/29/10 $ P Original Rec P % Return 7/2/10 P
Abaxis ABAX 26.8 2/2/09 15 79 21.18
Celera CRA 6.8 3/28/10 7 6.49
Genomic Health GHDX UR 12.58
Genoptix GXDX UR 17.17
GenProbe GPRO 48 2/2/09 45 7 46.25
Illumina ILMN 39 2/2/09 29 35 43.1
Immucor BLUD 18.58
Inverness IMA 39.7 2/2/09 25 37 25.8
MicroFluidics MFLU 7/6/10 0.77
NeoGen NEOG 7/6/10 25.7
Qiagen QGEN $23.10 3/15/10 21.5 12 19.38
Quidel QDEL $12.40 6/16/10 12.4 12.3
Sequenom SQNM 6.1 11/18/09 3.75 37 5.37
SeraCare SRLS 4 11/18/09 2.75 81 3.33

, , ,

No comments yet.

Leave a Reply